Neogenomics (NEO) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley
February 19, 2025 8:05 AM ESTMorgan Stanley analyst Tejas Savant lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Equalweight rating.
The analyst comments "Surprising albeit small miss on pharma budget flush spoils long track record of beats/raises; 25 guide/LRP in line w/ Jan prelim;... More
Neogenomics (NEO) PT Lowered to $18 at Jefferies
February 18, 2025 4:19 PM ESTJefferies analyst Tycho Peterson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $22.00) while maintaining a Buy rating.... More
Neogenomics (NEO) PT Lowered to $18 at Needham
February 18, 2025 4:01 PM ESTNeedham analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "NEO's 4Q24 revenue missed, while its EBITDA beat consensus. Management reiterated their 2025 revenue and EBITDA guidance. Revenue growth was... More
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO)
February 18, 2025 8:12 AM ESTRaymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).
The analyst comments "Quick take: This morning NeoGenomics reported 4Q results with the top line roughly 70 bp below consensus and nearly 200 bp below our view. With Clinical Services and Advanced Diagnostics now combined into one segment, visibility is lessened, but we estimate the former roughly matched consensus while... More
NeoGenomics (NEO) Tops Q4 EPS by 1c; offers guidance
February 18, 2025 7:06 AM ESTNeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $172 million versus the consensus estimate of $173.05 million.
GUIDANCE:
NeoGenomics sees FY2025 revenue of $735-745 million, versus the consensus of $735... More
